Renaissance Technologies LLC lessened its stake in shares of BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 8.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 329,660 shares of the company's stock after selling 31,500 shares during the quarter. Renaissance Technologies LLC owned about 1.75% of BrainsWay worth $3,109,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of BWAY. JPMorgan Chase & Co. increased its position in shares of BrainsWay by 61.9% in the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company's stock worth $226,000 after purchasing an additional 9,149 shares during the last quarter. Sei Investments Co. bought a new position in shares of BrainsWay in the fourth quarter worth approximately $149,000. ARK Investment Management LLC purchased a new stake in BrainsWay in the fourth quarter worth approximately $1,656,000. Finally, Rhumbline Advisers boosted its stake in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after buying an additional 2,144 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of BrainsWay in a research note on Wednesday, March 12th.
Get Our Latest Analysis on BrainsWay
BrainsWay Stock Up 3.3 %
BrainsWay stock traded up $0.30 during trading hours on Tuesday, hitting $9.25. The stock had a trading volume of 995 shares, compared to its average volume of 72,359. The stock's 50-day moving average price is $9.30 and its 200-day moving average price is $9.77. The stock has a market capitalization of $174.52 million, a P/E ratio of 91.56 and a beta of 1.17. BrainsWay Ltd. has a 12-month low of $4.80 and a 12-month high of $11.79.
BrainsWay Company Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
